The use of erythropoietin in gynecologic cancer patients

Purpose: To investigate the possible benefits of erythroproietin ingestion in patients with various gynecological cancers with proven severe iron deficiency anemia.

Method: Seven patients with gynecological cancer were included in the study. Nadir hematocrit values were found to be 20-24% before the initiation of recombinant human erythropoietin treatment. Initial therapy started at 50 units/kg/dose, three times weekly for a month. The dose was modified according to the rise of hemoglobin after a month's period. The dose was modified according to the rise of hemoglobin after a month's period. If the rise was greater than 2 g/dl the dose was changed to 25 units/kg two times weekly and if it was less than 2 g/dl it was changed to 25 units/kg three times weekly per month. Five patients were simultaneously given erythropoietin therapy and iron supplementation.

Results: We confirmed a rise in the hematocrit values which averaged 0.5-1.5% weekly till the upper limit. Reticulocyte and hematocrit values were higher in the erythropoietin plus iron group (five cases).

Conclusion: In this small series, erythropoietin appeared to be effective in treating severe iron deficiency in gynecologic cancer patients. Further investigation is needed to confirm these results.

Gynecologic cancers; Severe anemia; Erythropoietm

[1] Albertazzi A., Di Liberato L., Daniele F., Battiste! V., Colombi L.: "Efficacy and tolerability of recombinant human erythropoietin treatment in pre-dialysis patients: results of a multicenter study". Int. J. Artif. Organs., 1998, 21, 12.

[2] Cogan S., Blakemore K.: "Human immunodeficiency virs(perinatal infections)". In: The John Hopkins Manual of Gynecology and Obstetrics Lambrou N. C., Morse A. N., Wallach E. E. (eds). Philadelphia, 1999.

[3] Chudek J., Wiecek A., Kokot F., Grochal A., Switala J., Kanwiszer J.: "Serum erythropoietin concentration in women with uterine or ovarian tumors". Przegl-Lek, 1998, 55, 47.